MindRhythm
- Industry
- Medical Technology
- Founded Year
- 2019
- Headquarters
- 21710 Stevens Creek Boulevard, Cupertino, CA 95014, United States
- Employee Count
- 11
Key People
-
John Keane - Co-Founder, President, and CEO
Email: info@mindrhythm.com
-
Paul Lovoi, PhD - Co-Founder and CTO
Email: info@mindrhythm.com
-
Wade Smith, MD, PhD - Co-Founder and Chair of the Scientific Advisory Board
Email: info@mindrhythm.com
-
Corey Goodman, PhD - Chairman of the Board
Email: info@mindrhythm.com
-
Lisa Distenfield - Director of Clinical Affairs
Email: info@mindrhythm.com
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises experienced professionals with significant commercialization experience in the medical technology sector.
The leadership team includes individuals with proven track records in MedTech, enhancing the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: Stroke is a leading cause of death and disability, indicating a significant unmet clinical need.
With stroke being the fifth leading cause of death in the U.S., solutions like MindRhythm's Harmony device fulfill a crucial need in early detection and intervention.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing solutions, but MindRhythm offers a novel approach.
While there are established players in stroke detection, MindRhythm's non-invasive, rapid diagnostic tool provides a unique value proposition.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing non-invasive diagnostic tools presents moderate technical challenges.
Creating accurate, non-invasive devices requires overcoming specific technical challenges, but the company's expertise suggests these are surmountable.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents to protect its technology.
Securing patents will safeguard MindRhythm's innovations, providing a barrier to entry for competitors.
- Financing
-
Aspect: Medium
Summary: Raised $5M in seed funding from a diverse group of investors.
While the seed funding is substantial, further capital will likely be needed to support growth and commercialization efforts.
- Regulatory
-
Aspect: Running FIH
Summary: Conducting first-in-human trials for the Harmony device.
Advancing through clinical trials indicates a clear path toward regulatory approval, essential for market entry.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.3
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Stroke Detection and Monitoring
Year Post Launch | Market Penetration (%) |
---|---|
1 | 0.27 |
2 | 0.80 |
3 | 1.86 |
4 | 3.71 |
5 | 5.30 |
Key Takeaway
MindRhythm's innovative approach to stroke detection addresses a critical clinical need, supported by a strong team and promising market dynamics, though challenges in competition and financing remain.